WNT5A induces castration-resistant prostate cancer via CCL2 and tumour-infiltrating macrophages

BACKGROUND: Although the standard treatment for the patients with recurrent and metastatic prostate cancer (CaP) is androgen deprivation therapy, castration-resistant prostate cancer (CRPC) eventually emerges. Our previous report indicated that bone morphogenetic protein 6 (BMP6) induced CRPC via tu...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Cancer
Autors principals: Lee, Geun Taek, Kwon, Seok Joo, Kim, Jongmyung, Kwon, Young Suk, Lee, Nara, Hong, Jeong Hee, Jamieson, Christina, Kim, Wun-Jae, Kim, Isaac Yi
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group 2018
Matèries:
Translational Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5846063/
https://ncbi.nlm.nih.gov/pubmed/29381686
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2017.451
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars